News About: Pharm. Affairs
Ups and downs in prescription drug ranking
This first quarter’s ranking of prescription drugs was fluctuated due to patent expirations of original products.
Positions of Baraclude(BMS) and Celebrex(Pfizer) dropped due to their price cuts caused by the last y...
“There is a low chance for olmesartan therapies to cause trouble in Korea”
The Korean Society of Hypertension turned in “Reply to the French Olmesartan Issue” to the Ministry of Food and Drug Safety(MFDS) on April 19.
The reply is a follow-up of the MFDS’s request for the “Opinions and Dat...
Court prohibited manufacturing and sales of Glivec generics for GIST
The court accepted the Glivec’s use patent of gastrointestinal stromal tumor(GIST), and ordered to prohibit sales and manufacturing of its generics for the indication.
The 12th Civil Department, Seoul Central Distri...
‘Jardiance’ entering insurance benefit will expand SGLT-2 inhibitor market with Forxiga
Followed by AstraZeneca’s Forxiga and Astellas’s Suglat, Boehringer Ingelheim’s Jardiance entered the health insurance benefit door for the third time as a SGLT-2 inhibitor.
The last year’s prescriptions of Forxiga, ...
Lysozyme chloride & pronase single drugs to be suspended and collected
The Ministry of Food and Drug Safety(Minister Moon-gi Sohn) announced orders to suspend sales of ‘lysozyme chloride’ single drugs and ‘pronase’ single drug that are used to treat patients having difficulties in spitti...
Will Opdivo bring new turning point in treating lung cancer?
Opdivo has attracted interests if it could bring a new paradigm in treating lung cancer through acquiring the first domestic approval as a non-small cell lung cancer immune antibody.
Ono Pharma(CEO Ito Kynihiko) and ...
‘Eraser in mind,’ dementia costs more than 1 trillion medical expenses
It was observed occurrence of dementia starts get high in the 70s, and 3 of 10 people in the 90s or higher are treated for dementia. For the past 5 years, the number of treated patients and the medical expenses were i...
“We welcome decision to take corrective order on Merial refusing to animal drugs”
The Korean Pharmaceutical Association(President Chan-hui Jo, KPA) expressed an opinion to welcome the fact Merial South Korea, which rejected to supply animal drugs to pet pharmacies, received corrective orders from t...
Will BMS and Gilead divide hepatitis C treatment market?
BMS and Gilead have drawn a picture to divide the domestic hepatitis C treatment market.
According to the industry, the Ministry of Health and Welfare decided to register Sovaldi(generic name: sofosbuvir) and Harvon...
Mental war among domestic companies facing Viread’s salt-modified products
While the gigantic hepatitis B therapy, ‘Viread(tenofovir disoproxil fumarate)’ is expected to be expired in its substance patent next year, competition among domestic companies have already started over follow-up pro...
